Skip to content
Inciteful Med

Complications and Long-Term Monitoring for GCA

Last updated:

Giant cell arteritis (GCA) requires long-term monitoring to prevent serious complications like vision loss and aortic aneurysms. Up to 60% of patients experience relapses, often while tapering steroids, making regular blood tests, imaging, and symptom tracking essential.

Key Takeaways

  • • Permanent vision loss is the most severe immediate complication of untreated GCA.
  • • Up to one-third of GCA patients may develop an aortic aneurysm within 10 years, requiring regular imaging with CTA or MRA.
  • • Relapses happen in up to 60% of patients, typically while tapering steroid doses.
  • • Return of original symptoms like headaches, jaw pain, or vision changes requires immediate medical attention.
  • • Long-term monitoring includes a combination of symptom tracking, regular blood work for inflammation (ESR/CRP), and advanced imaging.

Giant cell arteritis (GCA) is a chronic condition, meaning that management often extends for years beyond the initial diagnosis [1][2]. While the emergency phase focuses on saving your vision, the long-term phase focuses on monitoring for relapses and protecting the health of your largest blood vessels [3][4].

Immediate and Severe Complications

If left untreated or if treatment is delayed, GCA can cause serious long-term complications due to the lack of blood flow to vital organs.

  • Vision Loss: The most common severe complication is permanent blindness, usually caused by Arteritic Anterior Ischemic Optic Neuropathy (AAION) [5][6]. This occurs when inflammation blocks the small arteries supplying the optic nerve [7][8].
  • Stroke: In a smaller number of cases, inflammation in the arteries supplying the brain can lead to a stroke [9]. This risk is highest in patients who have inflammation in the larger branches of the aorta, such as the vertebral arteries [9][10].

Long-Term Risks to the Aorta

Even after the initial symptoms (like headaches) are gone, the “silent” inflammation can sometimes continue in the aorta, the body’s largest artery [11][12].

  • Aneurysm and Dissection: GCA can weaken the wall of the aorta, causing it to bulge (aneurysm) or tear (dissection) [3][13]. Up to one-third of GCA patients may develop an aortic aneurysm within 10 years of their diagnosis [3].
  • Monitoring: Because these issues often have no symptoms, long-term monitoring is essential. Doctors use advanced imaging like CTA (Computed Tomography Angiography) or MRA (Magnetic Resonance Angiography) to check for widening of the aorta over time [14][15].

Managing Relapses

Relapses are very common in GCA, with as many as 60% of patients experiencing a return of symptoms, most often while they are tapering (gradually lowering) their steroid dose [4][16]. It is important to distinguish between a true GCA flare and normal steroid withdrawal symptoms, such as generalized aching, fatigue, or mood changes.

  • Red Flags: A “flare” or relapse is usually marked by the return of your original symptoms. You must notify your doctor immediately if you experience:
    • New or unusual headaches [17].
    • Return of jaw pain when eating or talking [17].
    • Sudden changes in vision [17].
    • New stiffness or aching in your shoulders and hips (PMR symptoms) [17].
  • Blood Tests: Your doctor will continue to monitor your ESR and CRP levels, though sometimes symptoms can return even when these blood tests look normal [18][19].

Life After Diagnosis

Living with GCA requires a partnership with your medical team. While the disease is chronic, most patients can achieve long-term remission with proper treatment and monitoring [20]. Staying vigilant for “red flag” symptoms and keeping up with regular imaging and blood work are the most important steps you can take to protect your long-term health [21][14].

Frequently Asked Questions

How often should I have imaging to check my aorta for aneurysms?
Because GCA can weaken the aorta and cause silent aneurysms, long-term imaging is essential. Your doctor will determine the right schedule for CTA or MRA scans to monitor your vascular health over time.
How do I know if my GCA is relapsing or if it is just steroid withdrawal?
A true GCA relapse usually involves the return of your original symptoms, such as new headaches, jaw pain, or vision changes. Steroid withdrawal often causes more generalized aching, fatigue, and mood changes.
Can I have a GCA relapse even if my blood tests are normal?
Yes, it is possible for GCA symptoms to return even when inflammatory markers like ESR and CRP look normal. Symptom tracking is just as important as regular blood work for identifying a flare.
Does having GCA increase my risk for a stroke?
Inflammation in the arteries supplying the brain can lead to a stroke in a small number of GCA cases. This risk is highest in patients with inflammation in the larger branches of the aorta, such as the vertebral arteries.
What should I do if my vision suddenly changes?
Sudden vision changes are a medical emergency in GCA and require immediate attention to prevent permanent blindness. You should contact your rheumatology or ophthalmology team immediately using your fast-track plan.

Questions for Your Doctor

  • • Given my diagnosis, how often should I have imaging (like a CTA or MRA) to check my aorta for aneurysms?
  • • What is the specific plan if I experience a flare-up of symptoms while tapering my steroids?
  • • Since I've had GCA, am I at a higher risk for a stroke, and what preventative measures should I take?
  • • If my blood tests (ESR/CRP) are normal but my symptoms return, does that still count as a relapse?
  • • Are there specific lifestyle changes, such as smoking cessation or blood pressure management, that will lower my risk of aortic complications?

Questions for You

  • • Are you keeping a symptom journal to track any return of headaches, jaw pain, or stiffness as you lower your steroid dose?
  • • Do you have a clear emergency contact or 'fast-track' plan for your rheumatology or ophthalmology team in case of sudden vision changes?
  • • Have you noticed any new, unusual chest or back pain that might need to be reported to your doctor?
  • • Are you attending all your scheduled follow-up blood tests, even when you feel well?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Treatment Patterns, Disease Burden, and Outcomes in Patients with Giant Cell Arteritis and Polymyalgia Rheumatica: A Real-World, Electronic Health Record-Based Study of Patients in Clinical Practice.

    Craig G, Knapp K, Salim B, et al.

    Rheumatology and therapy 2021; (8(1)):529-539 doi:10.1007/s40744-021-00290-3.

    PMID: 33638132
  2. 2

    Clinical Decision-Making Case: A Giant Headache.

    Portman M, Herman L

    Journal of education & teaching in emergency medicine 2025; (10(5)):CE239-CE259 doi:10.21980/J8.52322.

    PMID: 41522642
  3. 3

    Aortic disease in giant cell arteritis.

    Warrington KJ

    Seminars in arthritis and rheumatism 2025; (72S()):152677 doi:10.1016/j.semarthrit.2025.152677.

    PMID: 40021438
  4. 4

    Myalgias and Myopathies: Polymyalgia Rheumatica and Giant Cell Arteritis.

    Mansalis K

    FP essentials 2016; (440()):16-22.

    PMID: 26734832
  5. 5

    Giant Cell Arteritis: Updates and Controversies.

    Yu E, Chang JR

    Frontiers in ophthalmology 2022; (2()):848861 doi:10.3389/fopht.2022.848861.

    PMID: 38983551
  6. 6

    Two Cases of Segmental Disc Oedema and Normal Visual Acuity in Giant Cell Arteritis.

    Donaldson L, Shemesh AA, Margolin E

    Neuro-ophthalmology (Aeolus Press) 2019; (43(3)):201-204 doi:10.1080/01658107.2018.1490778.

    PMID: 31312246
  7. 7

    Arteritic Anterior Ischemic Optic Neuropathy (AAION) Associated with COVID-19 Infection: A Case Report and Review of the Literature.

    Shahraki K, Najafi A, Ashoori N, et al.

    Case reports in ophthalmological medicine 2023; (2023()):9009925 doi:10.1155/2023/9009925.

    PMID: 37492646
  8. 8

    Unilateral Central Retinal Artery Occlusion Revealing Giant Cell Arteritis: A Case Report.

    Lazaar H, Moumni A, Aziz A, et al.

    Cureus 2025; (17(3)):e80452 doi:10.7759/cureus.80452.

    PMID: 40225509
  9. 9

    Prognosis and long term outcome of stenotic large vessel involvement in giant cell arteritis.

    Maalouf G, Arnould B, Espitia O, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2026; doi:10.1002/art.70101.

    PMID: 41728983
  10. 10

    Neuro-Ophthalmologic Complications of Giant Cell Arteritis: Diagnosis and Treatment.

    Fein AS, Ko MW

    Seminars in neurology 2019; (39(6)):673-681 doi:10.1055/s-0039-1698761.

    PMID: 31847038
  11. 11

    Predictors of Dissection in Aortic Aneurysms From Giant Cell Arteritis.

    Kermani TA, Warrington KJ, Crowson CS, et al.

    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2016; (22(4)):184-7 doi:10.1097/RHU.0000000000000381.

    PMID: 27219304
  12. 12

    An unusual case of aortic rupture after deployment of a bare stent in the treatment of aortic dissection in a patient with giant-cell arteritis.

    Rynio P, Kazimierczak A, Gutowski P, Cnotliwy M

    Wideochirurgia i inne techniki maloinwazyjne = Videosurgery and other miniinvasive techniques 2017; (12(2)):194-198 doi:10.5114/wiitm.2017.67677.

    PMID: 28694908
  13. 13

    [SHOULD PATIENTS WITH GIANT CELL ARTERITIS BE TESTED FOR AORTIC ANEURYSMS?].

    Milchert M, Brzosko M

    Annales Academiae Medicae Stetinensis 2014; (60(2)):37-9.

    PMID: 26591105
  14. 14

    EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice.

    Dejaco C, Ramiro S, Duftner C, et al.

    Annals of the rheumatic diseases 2018; (77(5)):636-643 doi:10.1136/annrheumdis-2017-212649.

    PMID: 29358285
  15. 15

    EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update.

    Dejaco C, Ramiro S, Bond M, et al.

    Annals of the rheumatic diseases 2024; (83(6)):741-751 doi:10.1136/ard-2023-224543.

    PMID: 37550004
  16. 16

    Updates on the Prognosis of Giant Cell Arteritis: A Systematic Review.

    Abukanna AM, Alanazi YF, Alanazi FWS, et al.

    Cureus 2023; (15(12)):e50299 doi:10.7759/cureus.50299.

    PMID: 38089946
  17. 17

    Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations.

    Unizony S, McCulley TJ, Spiera R, et al.

    Arthritis research & therapy 2021; (23(1)):8 doi:10.1186/s13075-020-02377-8.

    PMID: 33407817
  18. 18

    Treatment failure in giant cell arteritis.

    Unizony SH, Bao M, Han J, et al.

    Annals of the rheumatic diseases 2021; (80(11)):1467-1474 doi:10.1136/annrheumdis-2021-220347.

    PMID: 34049857
  19. 19

    Temporal arteritis with erythrocyte sedimentation rate <50 mm/h: a clinical reminder.

    Cheema MR, Ismaeel SM

    Clinical interventions in aging 2016; (11()):185-8 doi:10.2147/CIA.S40919.

    PMID: 26966355
  20. 20

    Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial.

    Stone JH, Han J, Aringer M, et al.

    The Lancet. Rheumatology 2021; (3(5)):e328-e336 doi:10.1016/S2665-9913(21)00038-2.

    PMID: 38279390
  21. 21

    Imaging of giant cell arteritis - recent advances.

    Owen CE, Yates M, Liew DFL, et al.

    Best practice & research. Clinical rheumatology 2023; (37(1)):101827 doi:10.1016/j.berh.2023.101827.

    PMID: 37277245

This page is for informational purposes only and does not replace professional medical advice. Always contact your healthcare provider immediately if you experience vision changes or a return of GCA symptoms.

Stay up to date

Get notified when new research about Giant cell arteritis is published.

No spam. Unsubscribe anytime.